The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong ...
Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There
Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...
Healthcare Dive1d
GLP-1s are accelerating spending growth on traditional drugs, Evernorth research finds
Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey medications used to treat complex and chronic conditions, according to a new ...
HealthDay on MSN6d
No Weight Loss Benefit Seen for Neoadjuvant Semaglutide Before Weight Loss Surgery
HealthDay News — Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms of weight loss, according to a research letter published online March 5 in JAMA Surgery ...
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...
New Scientist16h
Why exercise is more important than ever when taking weight-loss drugs
GLP-1 drugs have revolutionised the treatment of obesity, but the very reason they are effective is also why it's vital to ...
New Atlas1d
Next-gen weight-loss drugs will be here within 12 months
It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...